pDONR223-YES1 Citations (3)

Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal

---

Articles Citing pDONR223-YES1

Articles
A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma. Sun J, Wang X, Tang B, Liu H, Zhang M, Wang Y, Ping F, Ding J, Shen A, Geng M. Theranostics. 2018 May 11;8(12):3256-3267. doi: 10.7150/thno.23964. eCollection 2018. PubMed
Cyclin-dependent kinase 1-mediated phosphorylation of YES links mitotic arrest and apoptosis during antitubulin chemotherapy. Wang Z, Chen X, Zhong MZ, Yang S, Zhou J, Klinkebiel DL, Karpf AR, Chen Y, Dong J. Cell Signal. 2018 Dec;52:137-146. doi: 10.1016/j.cellsig.2018.09.007. Epub 2018 Sep 15. PubMed
Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis. Han T, Jiang S, Zheng H, Yin Q, Xie M, Little MR, Yin X, Chen M, Song SJ, Beg AA, Pandolfi PP, Wan L. Nat Commun. 2019 Aug 16;10(1):3716. doi: 10.1038/s41467-019-11618-7. PubMed

If you have published an article using this material, please email us at to have your article added to this page.